
Mathea Sophia Galanski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1420694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect. Nanoscale Advances, 2021, 3, 249-262.	2.2	14
2	Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study. Scientific Reports, 2021, 11, 19354.	1.6	4
3	Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP) Tj ETQq1 1 Journal of Inorganic Chemistry, 2019, 2019, 856-864.	0.784314 r 1.0	rgBT /Overlock 3
4	Keggin-type polyoxotungstates as mushroom tyrosinase inhibitors - A speciation study. Scientific Reports, 2019, 9, 5183.	1.6	18
5	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. Inorganica Chimica Acta, 2019, 491, 76-83.	1.2	3
6	Synthesis, characterization, cytotoxic activity, and 19F NMR spectroscopic investigations of (OC-6-33)-diacetato(ethane-1,2-diamine)bis(3,3,3-trifluoropropanoato)platinum(IV) and its platinum(II) counterpart. Inorganica Chimica Acta, 2019, 490, 190-199.	1.2	6
7	The impact of whole human blood on the kinetic inertness of platinum(<scp>iv</scp>) prodrugs – an HPLC-ICP-MS study. Dalton Transactions, 2018, 47, 5252-5258.	1.6	20
8	Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. Scientific Reports, 2018, 8, 17198.	1.6	24
9	Development and Validation of Liquid Chromatography-Based Methods to Assess the Lipophilicity of Cytotoxic Platinum(IV) Complexes. Inorganics, 2018, 6, 130.	1.2	30
10	Synthesis, Characterization, and Time-Dependent NMR Spectroscopy Studies of (SP-4-2)-[(trans-1R,2R/1S,2S-15N2)-Cyclohexane-1,2-diamine][(13C2)oxalato]platinum(II). European Journal of Inorganic Chemistry, 2017, 2017, 2347-2354.	1.0	6
11	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. Journal of Inorganic Biochemistry, 2017, 174, 119-129.	1.5	25
12	Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands - Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2017, 2017, 4049-4054.	1.0	12
13	Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,Nâ€Đonor Ligands. European Journal of Inorganic Chemistry, 2017, 2017, 3115-3124.	1.0	13
14	A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques. Journal of Biological Inorganic Chemistry, 2017, 22, 1295-1304.	1.1	7
15	Oxaliplatin reacts with DMSO only in the presence of water. Dalton Transactions, 2017, 46, 8929-8932.	1.6	28
16	Lowâ€Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. European Journal of Inorganic Chemistry, 2017, 2017, 1713-1720.	1.0	20
17	Enhancing the Cytotoxic Activity of Anticancer Pt ^{IV} Complexes by Introduction of Lonidamine as an Axial Ligand. European Journal of Inorganic Chemistry, 2017, 2017, 1785-1791.	1.0	29
18	Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin. Bioinorganic Chemistry and Applications, 2017, 2017, 1-6.	1.8	5

#	Article	IF	CITATIONS
19	Vanadium(V) Complexes with Substituted 1,5-bis(2-hydroxybenzaldehyde)carbohydrazones and Their Use As Catalyst Precursors in Oxidation of Cyclohexane. Inorganic Chemistry, 2016, 55, 9187-9203.	1.9	49
20	Turbulent flow chromatography in combination with HPLC-ICP-MS for high-throughput analysis of free, intact metal based drugs in biomedical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1811-1817.	1.6	5
21	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. Journal of Inorganic Biochemistry, 2016, 160, 264-274.	1.5	40
22	Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches. Journal of Inorganic Biochemistry, 2016, 156, 1-13.	1.5	45
23	Synthesis, characterisation and cytotoxicity of (PHEN-4-MeDACH). Inorganica Chimica Acta, 2016, 441, 152-156.	1.2	4
24	Bis―and Tetrakis(carboxylato)platinum(IV) Complexes with Mixed Axial Ligands – Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2015, 12, 559-574.	1.0	7
25	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. Journal of Biological Inorganic Chemistry, 2015, 20, 89-99.	1.1	47
26	Influence of reducing agents on the cytotoxic activity of platinum(iv) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. Metallomics, 2015, 7, 1078-1090.	1.0	34
27	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	1.0	42
28	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in thetransPosition Exhibiting Exceptionally High Cytotoxicity. European Journal of Inorganic Chemistry, 2015, 2015, 1700-1708.	1.0	6
29	Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups — A rational approach toward exploiting the platinum(IV) prodrug strategy. Journal of Inorganic Biochemistry, 2015, 153, 259-271.	1.5	24
30	Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands – Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2014, 2014, 484-492.	1.0	28
31	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. Chemical Science, 2014, 5, 3135-3143.	3.7	87
32	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	2.9	49
33	Can neutral analytes be concentrated by transient isotachophoresis in micellar electrokinetic chromatography and how much?. Journal of Chromatography A, 2014, 1345, 212-218.	1.8	8
34	Inductively coupled plasma mass spectrometry for metallodrug development: Albumin binding and serum distribution of cytotoxic cis- and trans-isomeric platinum(II) complexes. Journal of Inorganic Biochemistry, 2014, 137, 40-45.	1.5	26
35	Platinum(IV) Complexes Featuring Axial (1, 4– ¹³ C ₂)Succinato Ligands – Synthesis, Characterization, and Preliminary Âłnvestigations in Cancer Cell Lysates. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1613-1620.	0.6	7
36	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. Journal of Biological Inorganic Chemistry, 2013, 18, 249-260.	1.1	16

#	Article	IF	CITATIONS
37	Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes. Journal of Medicinal Chemistry, 2013, 56, 330-344.	2.9	76
38	Bulky <i>N</i> (, <i>N</i>)-(Di)alkylethane-1,2-diamineplatinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes. Inorganic Chemistry, 2013, 52, 8151-8162.	1.9	32
39	Novel Oximato-Bridged Platinum(II) Di- and Trimer(s): Synthetic, Structural, and in Vitro Anticancer Activity Studies. Inorganic Chemistry, 2012, 51, 7153-7163.	1.9	22
40	Capillary zone electrophoresis and capillary zone electrophoresis–electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone) Tj ETQq0 0 0 rgBT /	Overkock 1	.0 Tuf650 617 1
41	Solid-phase synthesis of oxaliplatin–TATpeptide bioconjugates. Dalton Transactions, 2012, 41, 3001-3005.	1.6	65
42	Diamminetetrakis(carboxylato)platinum(IV) Complexes – Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2012, 9, 1840-1848.	1.0	11
43	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Clycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	2.9	34
44	Novel tetracarboxylatoplatinum(<scp>iv</scp>) complexes as carboplatin prodrugs. Dalton Transactions, 2012, 41, 14404-14415.	1.6	76
45	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. Molecular Pharmacology, 2012, 81, 719-728.	1.0	54
46	Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues. Journal of Biological Inorganic Chemistry, 2012, 17, 699-708.	1.1	14
47	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 465-474.	1.1	51
48	Synthesis, Characterization, and Cytotoxic Activity of Novel Potentially pH-Sensitive Nonclassical Platinum(II) Complexes Featuring 1,3-Dihydroxyacetone Oxime Ligands. Inorganic Chemistry, 2011, 50, 10673-10681.	1.9	34
49	Mono-carboxylated diaminedichloridoplatinum(<scp>iv</scp>) complexes – selective synthesis, characterization, and cytotoxicity. Dalton Transactions, 2011, 40, 8187-8192.	1.6	33
50	Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. European Journal of Medicinal Chemistry, 2011, 46, 5456-5464.	2.6	70
51	Lectin Conjugates as Biospecific Contrast Agents for MRI. Coupling of Lycopersicon esculentum Agglutinin to Linear Water-Soluble DTPA-Loaded Oligomers. Molecular Imaging and Biology, 2011, 13, 432-442.	1.3	12
52	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. Journal of Inorganic Biochemistry, 2011, 105, 46-51.	1.5	107
53	Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?. Journal of Inorganic Biochemistry, 2011, 105, 709-717.	1.5	35
54	The first example of MEEKCâ€ICPâ€IMS coupling and its application for the analysis of anticancer platinum complexes. Electrophoresis, 2010, 31, 1144-1150.	1.3	45

#	Article	IF	CITATIONS
55	{(1 <i>R</i> ,2 <i>R</i> ,4 <i>R</i>)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. Journal of Medicinal Chemistry, 2010, 53, 7356-7364.	2.9	51
56	Novel Cis- and Trans-Configured Bis(oxime)platinum(II) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Inorganic Chemistry, 2010, 49, 5669-5678.	1.9	49
57	Synthesis and structures of novel 1-methylcytosinato-bridged (ethylenediamine)platinum(ii) and platinum(iii) dinuclear complexes. Dalton Transactions, 2010, 39, 3633.	1.6	18
58	Novel Endothall ontaining Platinum(IV) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Chemistry and Biodiversity, 2008, 5, 2160-2170.	1.0	38
59	Novel and Mild Route to Phthalocyanines and 3â€Iminoisoindolinâ€1â€ones <i>via N</i> , <i>N</i> â€Diethylhydroxylamineâ€Promoted Conversion of Phthalonitriles and a Dramatic Solventâ€Dependence of the Reaction. Advanced Synthesis and Catalysis, 2008, 350, 135-142.	2.1	34
60	Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. Journal of Inorganic Biochemistry, 2008, 102, 2072-2077.	1.5	41
61	Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes. Tetrahedron, 2008, 64, 137-146.	1.0	10
62	Synthesis and structural peculiarities of gallium Complexes with novel paullone derivatives. Open Chemistry, 2008, 6, 340-346.	1.0	5
63	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	6.5	201
64	Unprecedented twofold intramolecular hydroamination in diam(m)ine-dicarboxylatodichloridoplatinum(iv) complexes – ethane-1,2-diamine <i>vs.</i> ammine ligands. Chemical Communications, 2008, , 1091-1093.	2.2	4
65	Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 55-73.	0.9	136
66	Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination. Journal of Medicinal Chemistry, 2007, 50, 6692-6699.	2.9	88
67	Antitumour metal compounds: more than theme and variations. Dalton Transactions, 2007, , 183-194.	1.6	767
68	DNA Interactions of pH-Sensitive, Antitumor Bis(aminoalcohol)dichloroplatinum(II) Complexesâ€,‡. Biochemistry, 2006, 45, 14817-14825.	1.2	27
69	Recent Developments in the Field of Anticancer Platinum Complexes. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 285-295.	0.8	201
70	Signal separation and determination of the enantiomeric purity of primary amines with (â^')-myrtenal – a 13C NMR study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2006, 65, 869-873.	2.0	11
71	An Entry to Novel Platinum Complexes: Carboxylation of Dihydroxoplatinum(IV) Complexes with Succinic Anhydride and Subsequent Derivatization. European Journal of Inorganic Chemistry, 2006, 2006, 2612-2617.	1.0	77
72	Bis(2-amino alcohol-κN)dicarboxylatoplatinum(II) Complexes – Elegant Synthesis via Ring-Opening of Bis(2-amino alcoholato-κ2N,O)platinum(II) Species with Dicarboxylic Acids. European Journal of Inorganic Chemistry, 2006, 2006, 2476-2483.	1.0	14

#	Article	IF	CITATIONS
73	Synthesis and Characterization of [(1R,2R)-trans-Diaminocyclohexane]platinum(II) Coordinated to Sulfur and Selenium Amino Acids. European Journal of Inorganic Chemistry, 2006, 2006, 3746-3752.	1.0	29
74	Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. European Journal of Medicinal Chemistry, 2005, 40, 1149-1155.	2.6	43
75	1,1'-Bis(oxazolin-2-yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(?3-allyl)Cl]2. European Journal of Inorganic Chemistry, 2005, 2005, 1589-1600.	1.0	14
76	Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: Separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis, 2005, 26, 878-884.	1.3	54
77	Synthesis, Cytotoxicity, and Structure-Activity Relationships of New Oxaliplatin Derivatives. Monatshefte Für Chemie, 2005, 136, 693-700.	0.9	16
78	Synthesis andin vitroAntitumor Potency of (Cyclohexane-1,2-Diamine)Platinum(II) Complexes with Aminotris(Methylenephosphonic Acid) as Bone-Seeking Ligand. Bioinorganic Chemistry and Applications, 2005, 3, 179-190.	1.8	8
79	Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry, 2005, 12, 2075-2094.	1.2	657
80	Tumour-inhibiting platinum(ii) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. Analyst, The, 2005, 130, 1383.	1.7	23
81	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis, 2004, 25, 1988-1995.	1.3	125
82	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-lº2N,O)platinum(II) – a representative of novel pH sensitive anticancer platinum complexes. Inorganica Chimica Acta, 2004, 357, 3237-3244.	1.2	46
83	Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. European Journal of Medicinal Chemistry, 2004, 39, 707-714.	2.6	51
84	Bis(2-aminobutanol)dichloroplatinum(II) Complexes and Their Singly and Doubly Ring-Closed Butanolato Species â^' Novel Prodrugs for Platinum-Based Antitumour Chemotherapy?. European Journal of Inorganic Chemistry, 2003, 2003, 2619-2625.	1.0	19
85	Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: Comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. Electrophoresis, 2003, 24, 2038-2044.	1.3	37
86	Synthesis, Characterization, and in Vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing aN,N-Bis(phosphonomethyl)glycine Ligandâ€. Journal of Medicinal Chemistry, 2003, 46, 4946-4951.	2.9	58
87	Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes. Dalton Transactions, 2003, , 3098.	1.6	8
88	Novel glucose-ferrocenyl derivatives: synthesis and properties. New Journal of Chemistry, 2002, 26, 671-673.	1.4	28
89	Platinum(iv)-mediated coupling of dione monoximes and nitriles: a novel reactivity pattern of the classic oxime-based chelating ligands. New Journal of Chemistry, 2002, 26, 1085-1091.	1.4	34
90	Carboxylation of 2-Hydroxyethyl-Substituted Tetrachloro(ethane-1,2-diamine)platinum(IV) Complexes — A New Synthetic Approach to Anticancer Platinum Compounds. European Journal of Inorganic Chemistry, 2002, 2002, 417-421.	1.0	7

#	Article	IF	CITATIONS
91	Studies on the chemistry of thienoannelatedO,N- andS,N-containing heterocycles. 25. Synthesis of new imidazolyl and pyrazolyl derivatives of thiophene as inhibitors of nitric oxide synthase. Journal of Heterocyclic Chemistry, 2002, 39, 857-861.	1.4	5
92	Reaction of (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum(II) with 5′-GMP under simulated physiological conditions, a CZE-ESI-MS study. Inorganica Chimica Acta, 2002, 339, 9-13.	1.2	21
93	Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. Journal of Inorganic Biochemistry, 2001, 86, 691-698.	1.5	77
94	Reaction monitoring of platinum(II) complex-5′-guanosine monophosphate adduct formation by ion exchange liquid chromatography/electrospray ionization mass spectrometry. Journal of Mass Spectrometry, 2001, 36, 742-753.	0.7	16
95	The Intramolecular Ligand-Exchange Reaction of (SP-4-2)-Dichlorobis(2-hydroxyethylamine)platinum(II) and (OC-6-22)-Tetrachlorobis(2-hydroxyethylamine)platinum(IV), a1H and15N,1H-HMQC NMR Study. European Journal of Inorganic Chemistry, 2001, 2001, 1145-1149.	1.0	15
96	[RuCl3ind3] and [RuCl2ind4]: Two New Ruthenium Complexes derived from the Tumor-inhibiting RuIII Compound HInd (OC-6-11)-[RuCl4ind2] (ind = indazole). Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2001, 627, 261-265.	0.6	12
97	Kinetics of binding properties of 5′-GMP with cisplatin under simulated physiological conditions by capillary electrophoresis. Biomedical Applications, 2000, 745, 211-219.	1.7	34
98	Is reduction required for antitumour activity of platinum(IV) compounds? Characterisation of a platinum(IV)–nucleotide adduct [enPt(OCOCH3)3(5′-GMP)] by NMR spectroscopy and ESI-MS. Inorganica Chimica Acta, 2000, 300-302, 783-789.	1.2	43
99	Capillary electrophoretic study of cisplatin interaction with nucleoside monophosphates, di- and trinucleotides. Journal of Chromatography A, 1999, 852, 337-346.	1.8	35
100	Carboxylation of dihydroxoplatinum(IV) complexes with acyl chlorides. Crystal structures of the trans-R,R- and trans-S,S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)-(cyclohexane-1,2-diamine)dichloroplatinum(IV). Inorganica Chimica Acta, 1997, 265, 271-274.	1.2	32
101	First Isolation of an Enol of a Carboxylic Acid by Complexation to an(Ethane-1,2-diamine)-platinum(II) Fragment, Angewandte Chemie International Edition in English, 1995, 34, 1103-1104.	4.4	15